Alkermes plc.
ALKSNasdaq
$52.72
↑ +1.5%Jul 17 close · end-of-day
Price
1Y↑ +80.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$8.8B
Enterprise Value
$9.8B
P/E
58.6
P/S
5.6
P/B
5.0
EV/EBITDA
42.2
PEG
—
FCF Yield
2.5%
Dividend Yield
—
Revenue (TTM)
$1.6B
Net Income (TTM)
$152.8M
Free Cash Flow (TTM)
$221.8M
Gross Margin
—
Operating Margin
12.3%
Net Margin
9.8%
ROE
8.7%
ROIC
5.2%
Debt / Equity
0.9
Net Cash
-$998.5M
Return 1Y
+79.6%
Company profile
Alkermes plc researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL, and VUMERITY. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate.
- CEO
- Richard F. Pops
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 2,280
- Website
- alkermes.com
Management & directors
- Gaffin David JosephEVP, CLO, Alkermes, Inc.
- Hopkinson Craig C.EVP R&D, Chief Medical Officer
- Parisi Samuel JosephVP, Finance (Interim PAO)
- Nichols Christian ToddSVP, Chief Commercial Officer
- Jackson Blair CurtisEVP, Chief Operating Officer
- Pops Richard FDirector and CEO, Alkermes plc
Roles derived from SEC Form 4 filings.
Earnings
ALKS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$392.9M↑ +28.2%
Diluted EPS-$0.40↓ -407.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.2B | $1.1B | $1.7B | $1.6B | $1.5B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$112.4M | $97.7M | -$6.1M | $414.1M | $420.6M | $254.0M |
| Net income | -$110.9M | -$48.2M | -$158.3M | $355.8M | $367.1M | $241.7M |
| Diluted EPS | -$0.70 | -$0.29 | -$0.97 | $2.10 | $2.17 | $1.43 |
| Operating cash flow | $82.8M | $101.7M | $21.0M | $401.4M | $439.1M | $520.8M |
| Free cash flow | $40.6M | $73.7M | -$17.2M | $353.3M | $405.6M | $480.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -10.8% | 8.3% | -0.5% | 24.9% | 27.0% | 17.2% |
| Net margin | -10.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $399.1M | $378.1M | $430.0M | $306.5M | $390.7M | $394.2M | $384.5M | $392.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $109.9M | $104.8M | $162.7M | $13.8M | $93.0M | $89.1M | $58.1M | -$48.3M |
| Net income | $91.4M | $92.4M | $146.5M | $22.5M | $87.1M | $82.8M | $49.4M | -$66.5M |
| Diluted EPS | $0.53 | $0.55 | $0.88 | $0.13 | $0.52 | $0.49 | $0.29 | -$0.40 |
| Operating cash flow | $146.0M | $81.6M | $190.4M | $98.8M | $150.2M | $101.7M | $170.1M | -$165.7M |
| Free cash flow | $138.9M | $73.3M | $180.6M | $88.7M | $137.2M | $84.4M | $170.0M | -$169.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 27.5% | 27.7% | 37.8% | 4.5% | 23.8% | 22.6% | 15.1% | -12.3% |
| Net margin | 22.9% | 24.4% | 34.1% | 7.3% | 22.3% | 21.0% | 12.8% | -16.9% |
Company news
Jul 14, 2026
Jul 13, 2026
Jul 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Gaffin David Joseph· EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $54.03 | $109,897.02 | filing |
| 2026-07-01 | Hopkinson Craig C.· EVP R&D, Chief Medical Officer | Sale | 8,300 | $51.46 | $427,128.79 | filing |
| 2026-07-01 | Hopkinson Craig C.· EVP R&D, Chief Medical Officer | Option exercise | 5,000 | $19.34 | $96,700.00 | filing |
| 2026-07-01 | Hopkinson Craig C.· EVP R&D, Chief Medical Officer | Sale | 700 | $52.13 | $36,491.98 | filing |
| 2026-06-12 | Wright Christopher I | Sale | 2,000 | $45.10 | $90,200.00 | filing |
| 2026-06-04 | Gaffin David Joseph· EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $43.05 | $87,563.70 | filing |
| 2026-06-01 | Hopkinson Craig C.· EVP R&D, Chief Medical Officer | Sale | 9,000 | $41.67 | $375,043.50 | filing |
| 2026-06-01 | Hopkinson Craig C.· EVP R&D, Chief Medical Officer | Option exercise | 5,000 | $19.34 | $96,700.00 | filing |
| 2026-05-29 | Parisi Samuel Joseph· VP, Finance (Interim PAO) | Sale | 16,217 | $42.36 | $687,007.26 | filing |
| 2026-05-29 | Parisi Samuel Joseph· VP, Finance (Interim PAO) | Option exercise | 12,825 | $19.34 | $248,035.50 | filing |
| 2026-05-29 | Parisi Samuel Joseph· VP, Finance (Interim PAO) | Option exercise | 3,392 | $20.03 | $67,941.76 | filing |
| 2026-05-21 | Cooke Shane | Tax withholding | 3,207 | $36.95 | $118,498.65 | filing |
| 2026-05-21 | Cooke Shane | Tax withholding | 3,207 | $36.95 | $118,498.65 | filing |
| 2026-05-21 | LAURENCIN CATO T | Tax withholding | 1,475 | $36.95 | $54,501.25 | filing |
| 2026-05-21 | MCKEON BRIAN P | Tax withholding | 1,475 | $36.95 | $54,501.25 | filing |
| 2026-05-21 | GAYNOR RICHARD | Tax withholding | 1,475 | $36.95 | $54,501.25 | filing |
| 2026-05-21 | snyderman nancy lynn MD | Tax withholding | 1,475 | $36.95 | $54,501.25 | filing |
| 2026-05-21 | Lurker Nancy | Tax withholding | 1,475 | $36.95 | $54,501.25 | filing |
| 2026-05-21 | Wilson Frank Anders | Tax withholding | 1,475 | $36.95 | $54,501.25 | filing |
| 2026-05-21 | Wright Christopher I | Tax withholding | 1,475 | $36.95 | $54,501.25 | filing |
| 2026-05-21 | Wright Christopher I | Option exercise | 6,142 | — | — | filing |
| 2026-05-21 | Cooke Shane | Option exercise | 6,142 | — | — | filing |
| 2026-05-21 | LAURENCIN CATO T | Option exercise | 6,142 | — | — | filing |
| 2026-05-21 | snyderman nancy lynn MD | Option exercise | 6,142 | — | — | filing |
| 2026-05-21 | MCKEON BRIAN P | Option exercise | 6,142 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.